Browse Studies — Arctuva

Phase 1

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-501 Administered Intravesically in Adult Participants With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle in…

Bladder (Urothelial, Transitional Cell) CancerNMIBCUrothelial Carcinoma Bladder+5 more

Estimated

~$10 – $8,750